White Paper
9 Questions To Ask Before You Develop A Fixed-Dosage Combination
Source: CoreRX, Inc.
By Todd Daviau, Ph.D., CoreRX Inc.In today's competitive pharmaceutical environment, building and maintaining market share is paramount. With dwindling pipelines, limited resources, and expiring patents, now, more than ever, combination products are being considered in drug development portfolios. However, regulatory hurdles, physician acceptance, and market strategy, are just a few considerations that one should address. This brief overview will cover specifics regarding fixed dosage combinations (FDCs), and will hopefully give companies thinking about combination products a better understanding to the challenges ahead.
Patients have already seen the benefit of combination products in areas such as oncology, cardiology, neurological, metabolic disorders, respiratory, HIV, as well as several other areas. Whether you are considering a solid, liquid, or a topical, marketing decision makers need to be well-informed in areas such as the current market, the regulatory environment, and most importantly in the scientific and formulation development challenges.
Register Today. It's Fast And Free.
The content you requested is only available to registered users of Pharmaceutical Online. By registering now, you'll get exclusive access to this piece of content and thousands of addtional articles and product reviews across our entire network of sites.
Already Registered? Sign In.
